A Combined Low-Density Lipoprotein Apheresis and Prednisone Therapy for Steroid-Resistant Primary Focal Segmental Glomerulosclerosis in Children

American Journal of Kidney Diseases

Volumn 42, Issue 6, 2003, Pages 1121-1130

  Hattori, Motoshi ^a   Chikamoto, Hiroko ^a   Akioka, Yuko ^a   Nakakura, Hyogo ^a   Ogino, Daisuke ^a   Matsunaga, Akira ^a   Fukazawa, Akira ^a   Miyakawa, Sanpei ^a   Khono, Miyuki ^a   Kawaguchi, Hiroshi ^a   Ito, Katsumi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Children; Low density lipoprotein apheresis (LDL A); Steroid resistant primary focal segmental glomerulosclerosis (SR FSGS)

Indexed keywords

CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; PREDNISONE; PROTEIN;

ADOLESCENT; APHERESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY FUNCTION; MALE; NEPHROTIC SYNDROME; PROSPECTIVE STUDY; PROTEINURIA; REMISSION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 10744228755     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.08.012     Document Type: Article

References (41)

1. Korbet SM: Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 9:1333-1340, 1998
2. Korbet SM, Schwartz MM, Lewis EL: Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J Kidney Dis 23:773-783, 1994
3. Tune BM, Mendoza SA: Treatment of the idiopathic nephrotic syndrome: Regimens and outcomes in children and adults. J Am Soc Nephrol 8:824-832, 1997
4. Tojo K, Sakai S, Miyahara T: Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS), Jpn J Nephrol 30:1153-1160, 1988
5. Hattori M, Ito K, Kawaguchi H, Tanaka T, Kubota R, Khono M: Treatment with a combination of low-density lipoprotein apheresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196-198, 1993
6. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S: Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9:257-264, 1994
7. Yokoyama K, Sakai S, Sigematsu T, et al: LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol 50:1-7, 1998
8. Ponticelli C, Passerini P: Alternative treatments for focal and segmental glomerular sclerosis. Clin Nephrol 55:345-348, 2001
9. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA: Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric segmental glomerulosclerosis: A long-term follow-up. Clin Nephrol 43:84-88, 1995
10. Gregory MJ, Smoyer WE, Sedman A, et al: Long-term cyclosporine therapy for pediatric nephrotic syndrome: A clinical and histologic analysis. J Am Soc Nephrol 7:543-549, 1996
11. Niaudet P: Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 125:981-986, 1994
12. Hino S, Takemura T, Okada M, et al: Follow-up study of children with nephrotic syndrome treated with a long-term moderate dose of cyclosporine. Am J Kidney Dis 31:932-939, 1998
13. Hattori M, Ito K, Konomoto T, Kawaguchi H, Yoshioka T, Khono M: Plasmapheresis as the sole therapy for rapidly progressive Henoch-Schö nlein purpura nephritis in children. Am J Kidney Dis 33:427-433, 1999
14. Sulowicz W, Stompor T: LDL-apheresis and immunoadsorption: Novel methods in the treatment of renal diseases refractory to conventional therapy. Nephrol Dial Transplant 18:Sv59-Sv62, 2003 (suppl 5)
15. Hattori M, Kurayama H, Koitabashi Y: Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J Am Soc Nephrol 12:1493-1500, 2001
16. National Heart, Lung and Blood Institute: Report of the Second Task Force on Blood Pressure Control in Children-1987. Pediatrics 79:1-25, 1987
17. Ponticelli C, Rizzoni G, Edefonti A, et al: A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43:1377-1384, 1993
18. Hattori M, Horita S, Yoshioka T, Yamaguchi Y. Kawaguchi H, Ito K: Mesangial phenotypic changes associated with cellular lesions in primary focal segmental glomerulosclerosis. Am J Kidney Dis 30:632-638, 1997
19. Demacker PNM, Hijmans AG, Vos-Jansen HE, van't Laar A, Jansen AP: A study of the use of polyethylene glycol in estimating cholesterol in high-density lipoprotein. Clin Chem 26:1775-1779, 1980
20. Schwartz GJ, Haycook GB, Edelmann CM, Spitzer A: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259-263, 1976
21. Cameron JS, Blandford G: The simple assessment of selectivity in heavy proteinuria. Lancet 2:242-244, 1966
22. Niaudet P, Habib R, Gagnadoux M, Tete M, Broyer M: Treatment of severe childhood nephrosis. Adv Nephrol 17:151-172, 1988
23. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr: Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. Pediatr Nephrol 10:590-593, 1996
24. Korbet SM: Treatment of primary focal segmental glomerulosclerosis. Kidney Int 62:2301-2310, 2002
25. Chishti AS, Sorof JM, Brewer ED, Kale AS: Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 38:754-760, 2001
26. Madore F, Lazarus JM, Brady HR: Therapeutic plasma exchange in renal diseases. J Am Soc Nephrol 7:367-386, 1996
27. Cattran DC, Rao P: Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72-79, 1998
28. Ingulli E, Singh A, Baqi N, Ahmad H, Moazami S, Tejani A: Aggressive, long-term cyclosporine therapy for steroid-resistant focal segmental glomerulosclerosis. J Am Soc Nephrol 5:1820-1825, 1995
29. Devarajan P, Spitzer A: Towards a biological characterization of focal segmental glomerulosclerosis. Am J Kidney Dis 39:625-636, 2002
30. Antignac C: Genetic models: Clues for understanding the pathogenesis of idiopathic nephrotic syndrome. J Clin Invest 109:447-449, 2002
31. Pollak MR: Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol 13:3016-3023, 2002
32. Keane WF: The role of lipids in renal disease: Future challenges. Kidney Int Suppl 75:S27-S31, 2000
33. Fried LF, Orchard TJ, Kasiske BL: Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59:260-269, 2001
34. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J: Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63:12-23, 2003
35. Hattori M, Ito K, Kawaguchi H, Yamaguchi Y: Probucol reduces renal injury in the ExHC rat. Nephron 67:459-468, 1994
36. Faucher C, Albert C, Beaufils H, Jouanneau C, Dupouet L: Remission of a refractory nephrotic syndrome after low-density lipoprotein apheresis based on dextran sulphate adsorption. Nephrol Dial Transplant 12:1037-1039, 1997
37. Petrichenko I, Daret D, Larrue J, Shakhov Y: Effect of VLDL on the inhibition of arachidonic acid transformation by dexamethasone in cultured smooth muscle cells. Biochim Biophys Acta 1166:183-187, 1993
38. Muso E, Mune M, Fujii Y, et al: Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408-415, 2001
39. Haack D, Schärer K, Asam-Tauscher A, Vecsei P: Glucocorticoid receptors in idiopathic nephrotic syndrome. Pediatr Nephrol 13:653-656, 1999
40. Laurent L, Philippon C, Lagrue G, Laurent G, Weil B, Rostoker G: Proteinuria selectivity index-Prognostic value in lipoid nephrosis and related diseases. Nephron 65:185-189, 1993
41. Bazzi C, Petrini C, Rizza V, Arrigo G, D'Amico G: A modern approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 58:1732-1741, 2000